KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Hims & Hers Health (HIMS) EBITDA (2019 - 2025)

Hims & Hers Health's EBITDA history spans 7 years, with the latest figure at $22.0 million for Q4 2025.

  • For Q4 2025, EBITDA fell 13.73% year-over-year to $22.0 million; the TTM value through Dec 2025 reached $131.0 million, up 4.09%, while the annual FY2025 figure was $131.0 million, 4.09% up from the prior year.
  • EBITDA for Q4 2025 was $22.0 million at Hims & Hers Health, up from $15.9 million in the prior quarter.
  • Across five years, EBITDA topped out at $76.0 million in Q3 2024 and bottomed at -$51.5 million in Q1 2021.
  • The 5-year median for EBITDA is -$7.4 million (2023), against an average of $3.0 million.
  • The largest annual shift saw EBITDA plummeted 853.08% in 2021 before it surged 1931.26% in 2024.
  • A 5-year view of EBITDA shows it stood at -$31.2 million in 2021, then surged by 65.69% to -$10.7 million in 2022, then surged by 111.7% to $1.3 million in 2023, then soared by 1931.26% to $25.5 million in 2024, then fell by 13.73% to $22.0 million in 2025.
  • Per Business Quant, the three most recent readings for HIMS's EBITDA are $22.0 million (Q4 2025), $15.9 million (Q3 2025), and $43.5 million (Q2 2025).